William Mariner Greenman Sells 101,919 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) CEO William Mariner Greenman sold 101,919 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total value of $299,641.86. Following the completion of the sale, the chief executive officer owned 5,053,036 shares of the company’s stock, valued at approximately $14,855,925.84. This represents a 1.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cerus Stock Performance

NASDAQ:CERS traded up $0.16 during trading hours on Thursday, reaching $3.16. 3,286,738 shares of the company’s stock were exchanged, compared to its average volume of 2,750,392. The firm has a market capitalization of $633.17 million, a price-to-earnings ratio of -63.20 and a beta of 1.77. The company has a 50-day moving average of $2.59 and a 200 day moving average of $2.29. The company has a quick ratio of 1.06, a current ratio of 1.63 and a debt-to-equity ratio of 0.47. Cerus Corporation has a 1-year low of $1.15 and a 1-year high of $3.21.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. The company had revenue of $59.89 million for the quarter, compared to analyst estimates of $55.68 million. Research analysts anticipate that Cerus Corporation will post -0.02 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its stake in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after purchasing an additional 1,064,133 shares during the last quarter. Kotler Kevin bought a new stake in Cerus during the fourth quarter valued at about $2,084,000. UBS Group AG increased its stake in shares of Cerus by 227.1% in the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company’s stock worth $2,354,000 after purchasing an additional 793,244 shares during the period. Globeflex Capital L P bought a new stake in shares of Cerus in the fourth quarter valued at approximately $1,076,000. Finally, Millennium Management LLC grew its stake in shares of Cerus by 17.6% in the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after acquiring an additional 519,301 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

CERS has been the topic of several analyst reports. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Zacks Research upgraded Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, May 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cerus has an average rating of “Hold” and an average target price of $4.00.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.